ICON plc (ICLR) shares rose 7.0% today, following the company’s July 28 announcement of a multi-year collaboration with Anthropic to use Claude across the clinical trial lifecycle. The partnership focuses on applying Claude to trial design, document workflows, data review, and other parts of clinical development. ICON had previously announced a June partnership with Microsoft, and investors may view the Anthropic deal as a sign of accelerating AI strategy. Sentiment also improved after a major peer in clinical research reported second-quarter revenue growth, stronger bookings, and raised full-year guidance on July 28, reinforcing optimism for the sector. ICON is scheduled to release its second-quarter 2026 results after the market close on July 29, with an earnings call on July 30.